Vertex Pharmaceuticals: Is the Recent Pullback a Reflection of Long Term Cash Flow Potential?
ByAinvest
Thursday, Feb 5, 2026 3:39 am ET1min read
VRTX--
Vertex Pharmaceuticals is undervalued by 34.9% according to a discounted cash flow analysis, which suggests the stock is undervalued based on projected cash flows. The analysis projects free cash flow of around $7.7b by 2030 and an intrinsic value of $722.30 per share, compared to the current share price of around $470. The stock has experienced a 3.7% decline over the past year and a 60.4% return over 3 years.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet